45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
2,192
Insurances with rates
6
CPT / HCPCS codes
2,156
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9347 | Tremelimumab-actl Soln for IV Infusion 300 MG/15ML | $49,335 | $39,468 | — | — | 13 |
| C1722 | ICD DYNAGEN MINI VR DF4 | $39,732 | $31,786 | — | — | 13 |
| J2350 | Ocrelizumab Soln For IV Infusion 300 MG/10ML | $32,696 | $26,156 | — | — | 13 |
| J0638 | Canakinumab Subcutaneous Inj 150 MG/ML | $32,070 | $25,656 | — | — | 13 |
| C1767 | IPG SPECTRA*NLU* | $29,575 | $23,660 | — | — | 13 |
| C1820 | STIM RESTOR SENS SURSCAN*OBS* | $27,125 | $21,700 | — | — | 13 |
| J9309 | Polatuzumab Vedotin-piiq For IV Solution 140 MG | $25,292 | $20,234 | — | — | 13 |
| J9272 | Dostarlimab-gxly IV Soln 500 MG/10ML (50 MG/ML) | $19,493 | $15,595 | — | — | 13 |
| J9022 | Atezolizumab IV Soln 1200 MG/20ML | $18,684 | $14,947 | — | — | 13 |
| J2327 | Risankizumab-rzaa IV Soln 600 MG/10ML (60 MG/ML) | $17,372 | $13,897 | — | — | 13 |
| J1930 | Lanreotide Acetate Extended Release Inj 120 MG/0.5ML | $16,235 | $12,988 | — | — | 13 |
| J3380 | Vedolizumab For IV Solution 300 MG | $15,860 | $12,688 | — | — | 13 |
| J9301 | Obinutuzumab Soln for IV Infusion 1000 MG/40ML (25 MG/ML) | $14,745 | $11,796 | — | — | 13 |
| J2323 | Natalizumab for IV Inj Conc 300 MG/15ML | $14,699 | $11,759 | — | — | 13 |
| J9144 | Daratumumab-Hyaluronidase-fihj Inj 1800-30000 MG-Unit/15ML | $13,906 | $11,125 | — | — | 13 |
| J1932 | Lanreotide Acetate Extended Release Inj 120 MG/0.5ML | $12,392 | $9,914 | — | — | 13 |
| J3101 | Tenecteplase For IV Soln Kit 50 MG | $12,160 | $9,728 | — | — | 39 |
| J9228 | Ipilimumab Soln for IV Infusion 50 MG/10ML (5 MG/ML) | $11,864 | $9,491 | — | — | 13 |
| J9223 | Lurbinectedin For IV Soln 4 MG | $10,910 | $8,728 | — | — | 13 |
| 33210 | SURG 33210 TPM INSERTION | $10,700 | $8,560 | — | — | 13 |
| J9271 | Pembrolizumab IV Soln 100 MG/4ML (25 MG/ML) | $10,690 | $8,552 | — | — | 39 |
| J0717 | Certolizumab Pegol Prefilled Syringe Kit 200 MG/ML | $10,535 | $8,428 | — | — | 26 |
| J0491 | Anifrolumab-fnia IV Soln 300 MG/2ML | $10,008 | $8,007 | — | — | 13 |
| J9306 | Pertuzumab Soln for IV Infusion 420 MG/14ML (30 MG/ML) | $9,306 | $7,445 | — | — | 13 |
| J2506 | Pegfilgrastim Soln Prefilled Syringe 6 MG/0.6ML | $9,273 | $7,419 | — | — | 13 |
| J3111 | Romosozumab-aqqg Inj Soln Prefilled Syringe 105 MG/1.17ML | $9,157 | $7,325 | — | — | 52 |
| 58563 | SURG 58563 HYSTEROSCOPY ENDOMETRIAL ABLATION | $9,064 | $7,251 | — | — | 13 |
| J3357 | Ustekinumab Soln Prefilled Syringe 45 MG/0.5ML | $8,998 | $7,198 | — | — | 13 |
| 81455 | NEURO-ONC EXPANDED PANEL 81455.800 | $8,904 | $7,123 | — | — | 13 |
| 81456 | NEURO ONC PANEL FUSIONS ONLY 81456.800 | $8,823 | $7,058 | — | — | 13 |
| C1762 | ALLO DENOVO NT ZIMM | $8,173 | $6,538 | — | — | 13 |
| J9042 | Brentuximab Vedotin For IV Soln 50 MG | $8,152 | $6,521 | — | — | 13 |
| Q5127 | Pegfilgrastim-fpgk Soln Prefilled Syringe 6 MG/0.6ML | $8,039 | $6,431 | — | — | 13 |
| 37765 | SURG 37765 STAB PHLEBT VARICOSE VEINS 1 XTR 10-20 STAB INCS | $7,699 | $6,159 | — | — | 13 |
| J9061 | Amivantamab-vmjw IV Soln 350 MG/7ML | $7,571 | $6,057 | — | — | 13 |
| 51040 | ED 51040 CYSTOSTOMY WDRN | $7,489 | $5,991 | — | — | 13 |
| Q5117 | Trastuzumab-anns For IV Soln 420 MG | $7,280 | $5,824 | — | — | 13 |
| J1306 | Inclisiran Sodium Subcutaneous Soln Pref Syr 284 MG/1.5ML | $7,038 | $5,631 | — | — | 13 |
| J9356 | Trastuzumab-Hyaluronidase-oysk Inj 600-10000 MG-Unit/5ML | $6,668 | $5,334 | — | — | 13 |
| 90375 | Rabies Immune Globulin (Human) Inj 1500 Unt/5ML (300 Unt/ML) | $6,618 | $5,295 | — | — | 26 |
| 41899 | ED 41899 UNLST PRC TTH RMPL OR STLZ | $6,601 | $5,281 | — | — | 13 |
| 81459 | MAYO COMPLETE SOLID TUMOR PANEL 81459.800 | $6,405 | $5,124 | — | — | 13 |
| 90378 | Palivizumab IM Soln 100 MG/ML | $6,348 | $5,079 | — | — | 13 |
| J2353 | Octreotide Acetate For IM Inj Kit 20 MG | $6,173 | $4,939 | — | — | 13 |
| J1459 | Immune Globulin (Human) IV Soln 40 GM/400ML | $5,963 | $4,771 | — | — | 26 |
| 95811 | PSG CPAP BIPAP 4+ PARAMETERS | $5,796 | $4,637 | — | — | 13 |
| J9354 | Ado-Trastuzumab Emtansine For IV Soln 100 MG | $5,786 | $4,628 | — | — | 13 |
| Q5116 | Trastuzumab-qyyp For IV Soln 420 MG | $5,515 | $4,412 | — | — | 13 |
| 74178 | CT ABD PELVIS WO THEN W CONT | $5,511 | $4,409 | — | — | 13 |
| 54700 | ED 54700 I&D EPIDIDYMIS TESTIS | $5,445 | $4,356 | — | — | 13 |
Showing top 50 of 2,192 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.